[Experimental research of targeting hTERT gene inhibited in hepatocellular carcinoma therapy by RNA interference]

Peng-Hui Zhang1, Zhi-Guang Tu, Ming-Qing Yang

  • 1Faculty of Laboratory Medicine, Chongqing University of Medical Sciences, Chongqing,400016, PR China.

Abstract

Insights

RNA interference effectively inhibits human telomerase reverse transcriptase (hTERT) gene expression in hepatocellular carcinoma cells and tumors. This targeted gene silencing offers a promising new avenue for neoplasm gene therapy.

Area of Science:

  • Molecular Biology
  • Gene Therapy
  • Oncology

Context:

  • RNA interference (RNAi) is a post-transcriptional gene silencing technology utilizing small interfering RNA (siRNA).
  • hTERT gene is highly expressed in hepatocellular carcinoma (HCC) and other malignant neoplasms.
  • Previous RNAi applications have shown promise in functional genomics and treating viral diseases, but not specifically for hTERT in HCC.

Purpose:

  • To investigate the feasibility and specificity of RNA interference for inhibiting human telomerase reverse transcriptase (hTERT) gene expression in hepatocellular carcinoma.
  • To evaluate the therapeutic potential of targeting hTERT in HCC through in vitro and in vivo studies.

Summary:

  • Small interfering RNAs (siRNAs) targeting hTERT were designed and delivered via the pTZU6+1-shRNA-hTERT vector into HCC SMMC-7721 cells and xenograft tumors in nude mice.
  • In vitro studies showed significant inhibition of hTERT mRNA and protein expression, leading to a 37.5% reduction in cell growth and altered cell cycle distribution (decreased S phase, increased G1/G0 phase).
  • In vivo studies demonstrated reduced tumor size, with significant decreases in hTERT mRNA (from 99.1% to 76.2%) and protein expression (from 87.2% to 61.8%) in the siRNA treatment group compared to controls.

Impact:

  • RNAi demonstrates specific inhibition of hTERT gene expression and proliferation in hepatocellular carcinoma cells.
  • This study validates RNAi as a potential novel gene therapy approach for managing hepatocellular carcinoma and other neoplasms.
  • Targeting hTERT via RNAi offers a new strategy for cancer treatment by disrupting a key oncogenic pathway.

Related Concept Videos

Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...